The Safety and Effectiveness of ISIS 2922 in Patients With AIDS Who Have Cytomegalovirus (CMV) of the Eyes

Exclusion Criteria

• •Co-existing Condition:
• •Patients with the following symptoms or conditions are excluded:
• •Eligibility to participate in a controlled clinical trial of ISIS 2922.
• •External ocular infection in eye to be treated.
• •Other herpetic infections of the retina, toxoplasma retinochoroiditis, or other diseases of the fundus in eye to be treated.
• •Ocular condition that would obstruct visualization of the posterior ocular structures in eye to be treated.
• •Retinal detachment in eye to be treated.
• •Known or suspected allergy to phosphorothioate oligonucleotides.
• •Silicone oil in eye to be treated.
• •Syphilis.
• •Clinical evidence of retinal pigment epithelial stippling.
• •Pseudoretinitis pigmentosa.
• •Concurrent Medication:
• •Excluded:
• •Foscarnet.
• •Mellaril, Stelazine, Thorazine, and Clofazimine.
• •Ethambutol / fluconazole combination.
• •Other investigational drugs for CMV retinitis.
• •Patients with the following prior conditions are excluded:
• •History of surgery to correct retinal detachment in eye to be treated.
• •History of ganciclovir implant for treatment of CMV retinitis.
• •History of intolerance to ISIS 2922.
• •History of syphilis.
• •Required:
• •Prior CMV retinitis therapy with ganciclovir, foscarnet, or ISIS 2922.